Novo Nordisk CEO Anticipates Continued US Supply Constraints for Weight-Loss Drug Wegovy Through 2024
Novo Nordisk’s Wegovy: CEO anticipates US supply challenges for 2024. Discover weight-loss breakthroughs today! Nordisk CEO’s Anticipation In a candid revelation, the CEO of Novo Nordisk, Lars Fruergaard Jorgensen, foresees ongoing supply limitations for the revolutionary weight-loss drug Wegovy within the United States. Despite the Danish pharmaceutical giant’s substantial investment in augmenting production, these constraints … Read more